04.30.26 -- End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight

Oxygen heterogeneity, caused by pressure variations and other factors in large-scale bioreactors, can significantly impact cell growth and product yield.

Selecting primary packaging for biologics requires evaluating formulation type, administration route, dosing needs, and stability to ensure safe, effective, home‑use‑ready drug products.

Early collaboration with an expert partner streamlines HME projects through optimized formulation, strong scale‑up, solid analytics, and adaptable technologies that boost performance.

Manufacturing complex and highly potent ADC treatments presents unique challenges. Get an insider look at how these treatments make it from development to commercialization.

Get access to the tools and expertise needed to support process development for biologic therapies from the clinical trial phase to commercialization.

Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

To meet mAb, bispecific, and multispecific expression needs, sponsors require a proven cell line platform that delivers high‑titer, stable expression for complex proteins.

Developing new delivery routes is essential for creating more effective treatments. We enable new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Strategic partnerships succeed through shared goals, transparency, cultural alignment, strong governance, and proactive communication, enabling faster development, reduced risk, and resilience.

As demand for self-administered therapies accelerates, autoinjectors, formally known as automated needle-based injection systems (NIS-AUTO), are playing a central role in modern medicine. 

Biotechs reshoring their supply chains to Western regions to mitigate risk and improve reliability require experienced partners to effectively manage these complex transitions.

Agentic AI is reshaping how FDA review, surveillance, and inspection activities operate, raising the bar for expectations. Explore how these changes will redefine regulatory engagement.

Discover how AI-powered modeling uncovers hidden patterns in DEL data, broadens chemical diversity, and accelerates decision-making to help teams prioritize compounds and move more efficiently.